Progress in the treatment of intracranial multidrug-resistant and extensively drug-resistant <i>Acinetobacter baumannii</i> infection_West China Medical Journal

Authors：

ZHAO Nan , SHAO Dongchuan , WANG Zeyi , ZHANG Wencai ,  MA Gang

Department of Neurosurgery, the First Hospital of Kunming, Kunming, Yunnan 650021, P. R. China;

Corresponding?author：

MA Gang, Email: 2198451485@qq.com

Keywords：

Intracranial infection; Acinetobacter baumannii; Drug-resistance; Treatment

DOI：

10.7507/1002-0179.202004406

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Intracranial Acinetobacter baumannii infection is a rare clinical disease with a gradual increase in incidence and extremely high mortality. With the continuous enhancement of bacterial resistance, more and more intracranial infections of multidrug-resistant and extensively drug-resistant Acinetobacter baumannii have appeared in the clinic, and its treatment has become a major challenge and problem faced by neurosurgeons. The treatment difficulties include the selection, usage and dosage of antimicrobial agents, as well as whether cerebrospinal fluid drainage is needed. A standardized treatment plan is still needed. In this paper, combining domestic and foreign literature, the treatment of intracranial infection of multidrug-resistant and extensively drug-resistant Acinetobacter baumannii will be reviewed in order to provide a reference for clinical treatment.

Citation： ZHAO Nan, SHAO Dongchuan, WANG Zeyi, ZHANG Wencai, MA Gang. Progress in the treatment of intracranial multidrug-resistant and extensively drug-resistant Acinetobacter baumannii infection. West China Medical Journal, 2021, 36(8): 1115-1119. doi: 10.7507/1002-0179.202004406 Copy

1.	Chen CH, Chang CY, Lin LJ, et al. Risk factors associated with postcraniotomy meningitis: a retrospective study. Medicine (Baltimore), 2016, 95(31): e4329.
2.	Schiaroli E, Pasticci MB, Cassetta MI, et al. Management of meningitis caused by multi drug-resistant Acinetobacter baumannii: clinical, microbiological and pharmacokinetic results in a patient treated with colistin methanesulfonate. Mediterr J Hematol Infect Dis, 2015, 7(1): e2015055.
3.	Piparsania S, Rajput N, Bhatambare G. Intraventricular polymyxin B for the treatment of neonatal meningo-ventriculitis caused by multi-resistant Acinetobacter baumannii--case report and review of literature. Turk J Pediatr, 2012, 54(5): 548-554.
4.	Karaiskos I, Galani L, Baziaka F, et al. Intraventricular and intrathecal colistin as the last therapeutic resort for the treatment of multidrug-resistant and extensively drug-resistant Acinetobacter baumannii ventriculitis and meningitis: a literature review. Int J Antimicrob Agents, 2013, 41(6): 499-508.
5.	Kim BN, Peleg AY, Lodise TP, et al. Management of meningitis due to antibiotic-resistant Acinetobacter species. Lancet Infect Dis, 2009, 9(4): 245-255.
6.	周華, 周建英, 俞云松. 中國鮑曼不動桿菌感染診治與防控專家共識解讀. 中國循證醫學雜志, 2016, 16(1): 26-29.
7.	Sullins AK, Abdel-Rahman SM. Pharmacokinetics of antibacterial agents in the CSF of children and adolescents. Paediatr Drugs, 2013, 15(2): 93-117.
8.	Jafarnejad S, Shab-Bidar S, Speakman JR, et al. Probiotics reduce the risk of antibiotic-associated diarrhea in adults (18-64 years) but not the elderly (> 65 years): a meta-analysis. Nutr Clin Pract, 2016, 31(4): 502-513.
9.	Cohen-Pfeffer JL, Gururangan S, Lester T, et al. Intracerebroventricular delivery as a safe, long-term route of drug administration. Pediatr Neurol, 2017, 67: 23-35.
10.	高建國, 葉英. 鮑曼不動桿菌顱內感染臨床特征與預后危險因素分析. 中華醫學雜志, 2018, 98(37): 2973-2977.
11.	Nau R, S?rgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev, 2010, 23(4): 858-883.
12.	Cawley MJ, Suh C, Lee S, et al. Nontraditional dosing of ampicillin-sulbactam for multidrug-resistant Acinetobacter baumannii meningitis. Pharmacotherapy, 2002, 22(4): 527-532.
13.	Sun L, Wang X, Li Z. Successful treatment of multidrug-resistant Acinetobacter baumannii meningitis with ampicillin sulbactam in primary hospital. Br J Neurosurg, 2018, 32(6): 642-645.
14.	徐亦農, 張聞聞, 孫吉林, 等. 1例多重耐藥鮑曼不動桿菌致顱內感染的治療體會. 感染、炎癥、修復, 2016, 17(1): 44-45.
15.	Rodvold KA, Gotfried MH, Cwik M, et al. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother, 2006, 58(6): 1221-1229.
16.	Tutuncu EE, Kuscu F, Gurbuz Y, et al. Tigecycline use in two cases with multidrug-resistant Acinetobacter baumannii meningitis. Int J Infect Dis, 2010, 14(Suppl 3): e224-e226.
17.	Sipahi OR, Mermer S, Demirdal T, et al. Tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii meningitis: results of the ege study. Clin Neurol Neurosurg, 2018, 172: 31-38.
18.	Lauretti L, D’Alessandris QG, Fantoni M, et al. First reported case of intraventricular tigecycline for meningitis from extremely drug-resistant Acinetobacter baumannii. J Neurosurg, 2017, 127(2): 370-373.
19.	Fang YQ, Zhan RC, Jia W, et al. A case report of intraventricular tigecycline therapy for intracranial infection with extremely drug resistant Acinetobacter baumannii. Medicine (Baltimore), 2017, 96(31): e7703.
20.	Long W, Yuan J, Liu J, et al. Multidrug resistant brain abscess due to Acinetobacter baumannii ventriculitis cleared by intraventricular and intravenous tigecycline therapy: a case report and review of literature. Front Neurol, 2018, 9: 518.
21.	焦永成, 孔海波, 劉愛軍, 等. 替加環素鞘內注射治療多重耐藥鮑曼不動桿菌顱內感染. 臨床神經外科雜志, 2020, 17(1): 90-93.
22.	Garnacho-Montero J, Dimopoulos G, Poulakou G, et al. Task force on management and prevention of Acinetobacter baumannii infections in the ICU. Intensive Care Med, 2015, 41(12): 2057-2075.
23.	Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America’s clinical practice guidelines for healthcare-associated ventriculitis and meningitis. Clin Infect Dis, 2017, 64(6): e34-e65.
24.	王明貴. 廣泛耐藥革蘭陰性菌感染的實驗診斷、抗菌治療及醫院感染控制: 中國專家共識. 中國感染與化療雜志, 2017, 17(1): 82-93.
25.	Markantonis SL, Markou N, Fousteri M, et al. Penetration of colistin into cerebrospinal fluid. Antimicrob Agents Chemother, 2009, 53(11): 4907-4910.
26.	Benifla M, Zucker G, Cohen A, et al. Successful treatment of Acinetobacter meningitis with intrathecal polymyxin E. J Antimicrob Chemother, 2004, 54(1): 290-292.
27.	Falagas ME, Bliziotis IA, Tam VH. Intraventricular or intrathecal use of polymyxins in patients with Gram-negative meningitis: a systematic review of the available evidence. Int J Antimicrob Agents, 2007, 29(1): 9-25.
28.	Rodríguez Guardado A, Blanco A, Asensi V, et al. Multidrug-resistant Acinetobacter meningitis in neurosurgical patients with intraventricular catheters: assessment of different treatments. J Antimicrob Chemother, 2008, 61(4): 908-913.
29.	Cascio A, Conti A, Sinardi L, et al. Post-neurosurgical multidrug-resistant Acinetobacter baumannii meningitis successfully treated with intrathecal colistin. A new case and a systematic review of the literature. Int J Infect Dis, 2010, 14(7): e572-e579.
30.	Moon C, Kwak YG, Kim BN, et al. Implications of postneurosurgical meningitis caused by carbapenem-resistant Acinetobacter baumannii. J Infect Chemother, 2013, 19(5): 916-919.
31.	Guo W, Guo SC, Li M, et al. Successful treatment of extensively drug-resistant Acinetobacter baumannii ventriculitis with polymyxin B and tigecycline - a case report. Antimicrob Resist Infect Control, 2018, 7: 22.
32.	Ye J, Tan LH, Shen ZP, et al. Polymyxin for the treatment of intracranial infections of extensively drug-resistant bacteria in children after neurosurgical operation. World J Pediatr, 2020, 16(5): 528-532.
33.	Pan S, Huang X, Wang Y, et al. Efficacy of intravenous plus intrathecal/intracerebral ventricle injection of polymyxin B for post-neurosurgical intracranial infections due to MDR/XDR Acinectobacter baumannii: a retrospective cohort study. Antimicrob Resist Infect Control, 2018, 7: 8.
34.	Fotakopoulos G, Makris D, Chatzi M, et al. Outcomes in meningitis/ventriculitis treated with intravenous or intraventricular plus intravenous colistin. Acta Neurochir (Wien), 2016, 158(3): 603-610.
35.	De Bonis P, Lofrese G, Scoppettuolo G, et al. Intraventricular versus intravenous colistin for the treatment of extensively drug resistant Acinetobacter baumannii meningitis. Eur J Neurol, 2016, 23(1): 68-75.
36.	Chusri S, Sakarunchai I, Kositpantawong N, et al. Outcomes of adjunctive therapy with intrathecal or intraventricular administration of colistin for post-neurosurgical meningitis and ventriculitis due to carbapenem-resistant Acinetobacter baumannii. Int J Antimicrob Agents, 2018, 51(4): 646-650.
37.	Pandey S, Li L, Deng XY, et al. Outcome following the treatment of ventriculitis caused by multi/extensive drug resistance gram negative bacilli; Acinetobacter baumannii and Klebsiella pneumonia. Front Neurol, 2019, 9: 1174.
38.	車江鵬, 黃瑾, 茆長玥, 等. 靜脈聯合鞘內或腦室內注射多黏菌素對多重耐藥鮑曼不動桿菌顱內感染療效及安全性meta分析. 中國抗生素雜志, 2020, 45(9): 929-934.
39.	Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis, 2004, 39(9): 1267-1284.
40.	Ng J, Gosbell IB, Kelly JA, et al. Cure of multiresistant Acinetobacter baumannii central nervous system infections with intraventricular or intrathecal colistin: case series and literature review. J Antimicrob Chemother, 2006, 58(5): 1078-1081.
41.	夏博銘, 朱磊, 張恒柱, 等. 多途徑聯合用藥治療廣泛耐藥鮑曼不動桿菌顱內感染1例報告并文獻復習. 臨床神經外科雜志, 2019, 16(3): 266-269.
42.	Zavascki AP, Bulitta JB, Landersdorfer CB. Combination therapy for carbapenem-resistant Gram-negative bacteria. Expert Rev Anti Infect Ther, 2013, 11(12): 1333-1353.
43.	裴紅莎, 劉寶來, 聶曉奇, 等. 磷霉素和頭孢哌酮/舒巴坦鈉序貫療法治療顱內多重耐藥鮑曼不動桿菌感染的臨床分析. 中國臨床神經外科雜志, 2016, 21(4): 232-233.
44.	Wu X, Wang L, Ye YZ, et al. Postoperative multidrug-resistant Acinetobacter baumannii meningitis successfully treated with intravenous doxycycline and intraventricular gentamicin: a case report. World J Clin Cases, 2019, 7(24): 4342-4348.
45.	Garnacho-Montero J, Amaya-Villar R. Multiresistant Acinetobacter baumannii infections: epidemiology and management. Curr Opin Infect Dis, 2010, 23(4): 332-339.
46.	楊林, 秦遜, 向琰, 等. 腰大池引流加鞘內注射治療泛耐藥鮑曼不動桿菌顱內感染的臨床療效分析. 國際神經病學神經外科學雜志, 2020, 47(3): 263-267.

1. Chen CH, Chang CY, Lin LJ, et al. Risk factors associated with postcraniotomy meningitis: a retrospective study. Medicine (Baltimore), 2016, 95(31): e4329.
2. Schiaroli E, Pasticci MB, Cassetta MI, et al. Management of meningitis caused by multi drug-resistant Acinetobacter baumannii: clinical, microbiological and pharmacokinetic results in a patient treated with colistin methanesulfonate. Mediterr J Hematol Infect Dis, 2015, 7(1): e2015055.
3. Piparsania S, Rajput N, Bhatambare G. Intraventricular polymyxin B for the treatment of neonatal meningo-ventriculitis caused by multi-resistant Acinetobacter baumannii--case report and review of literature. Turk J Pediatr, 2012, 54(5): 548-554.
4. Karaiskos I, Galani L, Baziaka F, et al. Intraventricular and intrathecal colistin as the last therapeutic resort for the treatment of multidrug-resistant and extensively drug-resistant Acinetobacter baumannii ventriculitis and meningitis: a literature review. Int J Antimicrob Agents, 2013, 41(6): 499-508.
5. Kim BN, Peleg AY, Lodise TP, et al. Management of meningitis due to antibiotic-resistant Acinetobacter species. Lancet Infect Dis, 2009, 9(4): 245-255.
6. 周華, 周建英, 俞云松. 中國鮑曼不動桿菌感染診治與防控專家共識解讀. 中國循證醫學雜志, 2016, 16(1): 26-29.
7. Sullins AK, Abdel-Rahman SM. Pharmacokinetics of antibacterial agents in the CSF of children and adolescents. Paediatr Drugs, 2013, 15(2): 93-117.
8. Jafarnejad S, Shab-Bidar S, Speakman JR, et al. Probiotics reduce the risk of antibiotic-associated diarrhea in adults (18-64 years) but not the elderly (> 65 years): a meta-analysis. Nutr Clin Pract, 2016, 31(4): 502-513.
9. Cohen-Pfeffer JL, Gururangan S, Lester T, et al. Intracerebroventricular delivery as a safe, long-term route of drug administration. Pediatr Neurol, 2017, 67: 23-35.
10. 高建國, 葉英. 鮑曼不動桿菌顱內感染臨床特征與預后危險因素分析. 中華醫學雜志, 2018, 98(37): 2973-2977.
11. Nau R, S?rgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev, 2010, 23(4): 858-883.
12. Cawley MJ, Suh C, Lee S, et al. Nontraditional dosing of ampicillin-sulbactam for multidrug-resistant Acinetobacter baumannii meningitis. Pharmacotherapy, 2002, 22(4): 527-532.
13. Sun L, Wang X, Li Z. Successful treatment of multidrug-resistant Acinetobacter baumannii meningitis with ampicillin sulbactam in primary hospital. Br J Neurosurg, 2018, 32(6): 642-645.
14. 徐亦農, 張聞聞, 孫吉林, 等. 1例多重耐藥鮑曼不動桿菌致顱內感染的治療體會. 感染、炎癥、修復, 2016, 17(1): 44-45.
15. Rodvold KA, Gotfried MH, Cwik M, et al. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother, 2006, 58(6): 1221-1229.
16. Tutuncu EE, Kuscu F, Gurbuz Y, et al. Tigecycline use in two cases with multidrug-resistant Acinetobacter baumannii meningitis. Int J Infect Dis, 2010, 14(Suppl 3): e224-e226.
17. Sipahi OR, Mermer S, Demirdal T, et al. Tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii meningitis: results of the ege study. Clin Neurol Neurosurg, 2018, 172: 31-38.
18. Lauretti L, D’Alessandris QG, Fantoni M, et al. First reported case of intraventricular tigecycline for meningitis from extremely drug-resistant Acinetobacter baumannii. J Neurosurg, 2017, 127(2): 370-373.
19. Fang YQ, Zhan RC, Jia W, et al. A case report of intraventricular tigecycline therapy for intracranial infection with extremely drug resistant Acinetobacter baumannii. Medicine (Baltimore), 2017, 96(31): e7703.
20. Long W, Yuan J, Liu J, et al. Multidrug resistant brain abscess due to Acinetobacter baumannii ventriculitis cleared by intraventricular and intravenous tigecycline therapy: a case report and review of literature. Front Neurol, 2018, 9: 518.
21. 焦永成, 孔海波, 劉愛軍, 等. 替加環素鞘內注射治療多重耐藥鮑曼不動桿菌顱內感染. 臨床神經外科雜志, 2020, 17(1): 90-93.
22. Garnacho-Montero J, Dimopoulos G, Poulakou G, et al. Task force on management and prevention of Acinetobacter baumannii infections in the ICU. Intensive Care Med, 2015, 41(12): 2057-2075.
23. Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America’s clinical practice guidelines for healthcare-associated ventriculitis and meningitis. Clin Infect Dis, 2017, 64(6): e34-e65.
24. 王明貴. 廣泛耐藥革蘭陰性菌感染的實驗診斷、抗菌治療及醫院感染控制: 中國專家共識. 中國感染與化療雜志, 2017, 17(1): 82-93.
25. Markantonis SL, Markou N, Fousteri M, et al. Penetration of colistin into cerebrospinal fluid. Antimicrob Agents Chemother, 2009, 53(11): 4907-4910.
26. Benifla M, Zucker G, Cohen A, et al. Successful treatment of Acinetobacter meningitis with intrathecal polymyxin E. J Antimicrob Chemother, 2004, 54(1): 290-292.
27. Falagas ME, Bliziotis IA, Tam VH. Intraventricular or intrathecal use of polymyxins in patients with Gram-negative meningitis: a systematic review of the available evidence. Int J Antimicrob Agents, 2007, 29(1): 9-25.
28. Rodríguez Guardado A, Blanco A, Asensi V, et al. Multidrug-resistant Acinetobacter meningitis in neurosurgical patients with intraventricular catheters: assessment of different treatments. J Antimicrob Chemother, 2008, 61(4): 908-913.
29. Cascio A, Conti A, Sinardi L, et al. Post-neurosurgical multidrug-resistant Acinetobacter baumannii meningitis successfully treated with intrathecal colistin. A new case and a systematic review of the literature. Int J Infect Dis, 2010, 14(7): e572-e579.
30. Moon C, Kwak YG, Kim BN, et al. Implications of postneurosurgical meningitis caused by carbapenem-resistant Acinetobacter baumannii. J Infect Chemother, 2013, 19(5): 916-919.
31. Guo W, Guo SC, Li M, et al. Successful treatment of extensively drug-resistant Acinetobacter baumannii ventriculitis with polymyxin B and tigecycline - a case report. Antimicrob Resist Infect Control, 2018, 7: 22.
32. Ye J, Tan LH, Shen ZP, et al. Polymyxin for the treatment of intracranial infections of extensively drug-resistant bacteria in children after neurosurgical operation. World J Pediatr, 2020, 16(5): 528-532.
33. Pan S, Huang X, Wang Y, et al. Efficacy of intravenous plus intrathecal/intracerebral ventricle injection of polymyxin B for post-neurosurgical intracranial infections due to MDR/XDR Acinectobacter baumannii: a retrospective cohort study. Antimicrob Resist Infect Control, 2018, 7: 8.
34. Fotakopoulos G, Makris D, Chatzi M, et al. Outcomes in meningitis/ventriculitis treated with intravenous or intraventricular plus intravenous colistin. Acta Neurochir (Wien), 2016, 158(3): 603-610.
35. De Bonis P, Lofrese G, Scoppettuolo G, et al. Intraventricular versus intravenous colistin for the treatment of extensively drug resistant Acinetobacter baumannii meningitis. Eur J Neurol, 2016, 23(1): 68-75.
36. Chusri S, Sakarunchai I, Kositpantawong N, et al. Outcomes of adjunctive therapy with intrathecal or intraventricular administration of colistin for post-neurosurgical meningitis and ventriculitis due to carbapenem-resistant Acinetobacter baumannii. Int J Antimicrob Agents, 2018, 51(4): 646-650.
37. Pandey S, Li L, Deng XY, et al. Outcome following the treatment of ventriculitis caused by multi/extensive drug resistance gram negative bacilli; Acinetobacter baumannii and Klebsiella pneumonia. Front Neurol, 2019, 9: 1174.
38. 車江鵬, 黃瑾, 茆長玥, 等. 靜脈聯合鞘內或腦室內注射多黏菌素對多重耐藥鮑曼不動桿菌顱內感染療效及安全性meta分析. 中國抗生素雜志, 2020, 45(9): 929-934.
39. Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis, 2004, 39(9): 1267-1284.
40. Ng J, Gosbell IB, Kelly JA, et al. Cure of multiresistant Acinetobacter baumannii central nervous system infections with intraventricular or intrathecal colistin: case series and literature review. J Antimicrob Chemother, 2006, 58(5): 1078-1081.
41. 夏博銘, 朱磊, 張恒柱, 等. 多途徑聯合用藥治療廣泛耐藥鮑曼不動桿菌顱內感染1例報告并文獻復習. 臨床神經外科雜志, 2019, 16(3): 266-269.
42. Zavascki AP, Bulitta JB, Landersdorfer CB. Combination therapy for carbapenem-resistant Gram-negative bacteria. Expert Rev Anti Infect Ther, 2013, 11(12): 1333-1353.
43. 裴紅莎, 劉寶來, 聶曉奇, 等. 磷霉素和頭孢哌酮/舒巴坦鈉序貫療法治療顱內多重耐藥鮑曼不動桿菌感染的臨床分析. 中國臨床神經外科雜志, 2016, 21(4): 232-233.
44. Wu X, Wang L, Ye YZ, et al. Postoperative multidrug-resistant Acinetobacter baumannii meningitis successfully treated with intravenous doxycycline and intraventricular gentamicin: a case report. World J Clin Cases, 2019, 7(24): 4342-4348.
45. Garnacho-Montero J, Amaya-Villar R. Multiresistant Acinetobacter baumannii infections: epidemiology and management. Curr Opin Infect Dis, 2010, 23(4): 332-339.
46. 楊林, 秦遜, 向琰, 等. 腰大池引流加鞘內注射治療泛耐藥鮑曼不動桿菌顱內感染的臨床療效分析. 國際神經病學神經外科學雜志, 2020, 47(3): 263-267.

Previous Article
Mechanism of Epstein-Barr virus latent infection-related genes in tumors caused by them
Next Article
Virtual reality for the upper limb motor rehabilitation after stroke

West China Medical Journal

Progress in the treatment of intracranial multidrug-resistant and extensively drug-resistant Acinetobacter baumannii infection

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content